Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics
Clinical trials sponsored by Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics, explained in plain language.
Biotech subsidiary focused on developing therapies, owned by Structure Therapeutics.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill aims to help people with diabetes shed pounds and control blood sugar
Disease control OngoingThis study tests a new daily pill, aleniglipron, in 58 adults with type 2 diabetes who are overweight or obese. The main goal is to check if the drug is safe and tolerable at different doses. Researchers will also measure weight loss and blood sugar changes. The study is not yet …
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New pill could melt fat in people with obesity
Disease control OngoingThis study tests a new oral drug called aleniglipron (GSBR-1290) in 71 adults with obesity (BMI ≥30). Participants take the drug or a placebo daily for 40 weeks. Researchers measure changes in body fat, waist size, and weight using special scans. The goal is to see if the drug sa…
Phase: PHASE2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC